TG 1042

Drug Profile

TG 1042

Alternative Names: Ad-IFN-γ-IL2; Ad-IFNγ; Adenovirus interferon gamma; Asn-002 - Ascend; TG-1042

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Transgene
  • Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
  • Class Antineoplastics; Gene therapies; Immunotherapies; Interferons
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Basal cell cancer
  • No development reported Malignant melanoma
  • Discontinued Cutaneous B-cell lymphoma; Cutaneous T cell lymphoma

Most Recent Events

  • 07 Nov 2016 Interim efficacy data from a phase I/II trial in Basal cell cancer released by Ascend Biopharmaceuticals
  • 01 Sep 2015 Phase-I/II clinical trials in Basal cell cancer in Australia (Intratumoural) (NCT02550678)
  • 03 Jul 2013 TG 1042 licensed to Ascend Biopharmaceuticals for the treatment of Basal cell cancer and two other cancer indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top